House committee plans to examine FDA's drug-safety efforts

03/4/2010 | Reuters

The House Energy and Commerce Committee scheduled a hearing Wednesday to look into the FDA's drug-safety efforts amid criticism that the agency is slow to respond to reports of adverse reactions to approved treatments.

View Full Article in:

Reuters